Christopher Flores

President and Chief Research and Development Officer, Doloromics

Prior to Doloromics, Flores led a cross-functional team within Janssen’s Neuroscience Therapeutic Area in maximizing the benefit to patients from the company’s glutamatergic medicines.  Flores originally joined Johnson & Johnson in 2002 and over the next 16 years held several executive positions within its pharmaceutical and consumer sectors, including Head of Pain Discovery, Senior Director of External Innovation and Pain Franchise Strategy Leader for Janssen Neuroscience as well as Head of Emerging Science and Innovation Strategy for Johnson & Johnson Consumer R&D. 

Before joining Johnson & Johnson, Flores was a P.R.A.T. Fellow at the National Institute of Neurological Disorders and Stroke, an Assistant Professor of Oral Sciences at the University of Minnesota and a tenured Associate Professor at the University of Texas Health Science Center at San Antonio in the Departments of Pharmacology and Endodontics, where he was also Director of Research. For the better part of his 35-yr career in government, academia and industry, Flores has contributed substantively to our mechanistic understanding of pain and neurogenic inflammation at the molecular, cellular, system and behavioral levels and has led the discovery of several new molecular entities that are at various stages of development for the treatment of pain.